Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
18.45 +0.25 +1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Founded
2013
CEO
Dr. Ryan J. Watts, PhD
Employees
503
Headquarters
San Francisco, California, United States of America
Fiscal year end
12-31
Website
denalitherapeutics.com

Company profile

Exchange
US
Symbol
DNLI
Market-cap rank
#2454
Listing date
2017-12-08
Market cap
2.96B
Float cap
2.87B
Shares out
160.29M
Float shares
155.54M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Denali Therapeutics discussion 0 comments

Add a comment